Philippines Business News API

{
    "totalArticles": 278664,
    "articles": [
        {
            "id": "afeb911ad4dcbcf6ada3c83c7d633210",
            "title": "Amazon Job Search Success: How Rethinking My Strategy Landed Me a Role",
            "description": "Jugal Bhatt struggled to land interviews after moving to the US for grad school. Rethinking his job search helped him land a tech job at Amazon.",
            "content": "This 'as-told-to' essay is based on a conversation with Jugal Bhatt, a 24-year-old software engineer at Amazon based in Phoenix. Business Insider has verified his employment with documentation. This essay has been edited for length and clarity.\nEight... [4732 chars]",
            "url": "https://www.businessinsider.com/amazon-job-search-success-strategy-tech-software-engineering-role-interview-2025-11",
            "image": "https://i.insider.com/69246f0289026fbb4d0e425c?width=1200&format=jpeg",
            "publishedAt": "2025-11-30T10:52:00Z",
            "lang": "en",
            "source": {
                "id": "3349d5cc8abff1623266825fbe6b0f68",
                "name": "Business Insider",
                "url": "https://www.businessinsider.com"
            }
        },
        {
            "id": "eba0f27bce73e6dd1c38ac378bf249d3",
            "title": "Day Traders Tell Us the Hardest Part About Making Money in Markets",
            "description": "Over 35% of day traders said they believed their biggest challenge was managing emotions or dealing with losses, according to one survey.",
            "content": "Day trading isn't so much a science as it is an emotional test.\nThat's the secret to day trading that outsiders don't seem to understand, retail traders told me at a recent happy hour in New York's Financial District.\nThat might come as a surprise to... [5413 chars]",
            "url": "https://www.businessinsider.com/day-trading-strategies-hard-making-money-volatile-managing-emotions-2025-11",
            "image": "https://i.insider.com/69260c77abd5e944effb7d69?width=1200&format=jpeg",
            "publishedAt": "2025-11-30T10:31:00Z",
            "lang": "en",
            "source": {
                "id": "3349d5cc8abff1623266825fbe6b0f68",
                "name": "Business Insider",
                "url": "https://www.businessinsider.com"
            }
        },
        {
            "id": "093b142f45f806219d5fbd47227316b6",
            "title": "1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development",
            "description": "- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%,...",
            "content": "- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the o... [4793 chars]",
            "url": "https://www.prnewswire.com/news-releases/ascletis-selects-its-first-oral-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302628537.html",
            "image": "https://www.prnewswire.com/content/dam/prnewswire/icons/2019-Q4-PRN-Icon-32-32.png",
            "publishedAt": "2025-11-30T10:15:00Z",
            "lang": "en",
            "source": {
                "id": "4e4307a07d2ce1e31acaf932954d3dd9",
                "name": "PR Newswire",
                "url": "https://www.prnewswire.com"
            }
        }
    ]
}